CNS Pharmaceuticals Inc CNSP

Healthcare Biotechnology

CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The Company's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.

NDAQ:CNSP - Post by User

CNS Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

(316)
•••

Post by Iseneschalon Apr 14, 2023 2:57pm

96 Views

Post# 35395789

CNSP....thru the $2.13....halted again.

How can a person make a decision on this......Mr. Maggot can do what ever he wants. And to top this manip off ...No News !!!!

All I know is...the last financing was at $3.17.....good chance this will top that.... I should have kept this obviously but to pass up the profit at $2.00 and watch it go to $1.09 after would have been a travesty

If I was blind I would not have left any on the table ....but that not me. GLTA

<< Previous

Bullboard Posts

Next >>

Take advantage of setbacks among industry leaders: A strategic entry into Almonty Industries, Rheinmetall, and D-Wave Quantum